We are live on !
Find out more
Broadfin Capital Portfolio holdings
AUM
$747M
Turnover
50%
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$206M
(+38%)
Cap. Flow
-$7.76M
Cap. Flow % of AUM
Cap. Flow %
-1.04%
Top 10 Holdings %
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16
Avg Time Held
Equity + Options
1.4
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$15.6M |
| 2 |
STAAR Surgical
STAA
|
+$15.2M |
| 3 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$14.8M |
| 4 |
Lantheus
LNTH
|
+$12.5M |
| 5 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$16.2M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$13.6M |
| 3 |
NEVRO CORP.
NVRO
|
+$12.9M |
| 4 |
WMGI
Wright Medical Group Inc
WMGI
|
+$12.8M |
| 5 |
AbbVie
ABBV
|
+$11.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.91% |
| 2 | Miscellaneous | 46.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Relmada Therapeutics
RLMD
$349M
| $8.61M | 1.15% |
+220,724
| New | +$6.71M |
2019 Q4
0 quarters
|
|
27
Aurinia Pharmaceuticals
AUPH
$2.24B
| $8.1M | 1.09% |
+400,000
| New | +$3.68M |
2019 Q4
0 quarters
|
|
|
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
| $7.77M | 1.04% |
1,029,012
-2,073,661
| -67% | -$11M |
2013 Q2
26 quarters
|
|
29
Exicure
XCUR
$6.87M
| $7.74M | 1.04% |
18,052
+2,639
| +17% | +$1.08M |
2019 Q3
1 quarter
|
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $7.03M | 0.94% |
134,937
-3,100
| -2% | -$142K |
2017 Q2
10 quarters
|
|
31
ICU Medical
ICUI
$4.17B
| $5.61M | 0.75% |
30,000
| – | – |
2019 Q3
1 quarter
|
|
|
LMNX
32
DELISTED
Luminex Corp
LMNX
| $4.81M | 0.64% |
+207,553
| New | +$4.28M |
2019 Q4
0 quarters
|
|
|
33
CALL
Alkermes
ALKS
$7.32B
| $4.08M | 0.55% |
+200,000
| New | +$3.98M |
2019 Q4
0 quarters
|
|
34
DELISTED
Strata Skin Sciences
SSKN
| $3.83M | 0.51% |
183,937
-107,755
| -37% | -$2.45M |
2015 Q1
19 quarters
|
|
35
AnaptysBio
ANAB
$1.46B
| $3.6M | 0.48% |
+221,600
| New | +$5.24M |
2019 Q4
0 quarters
|
|
36
Aclaris Therapeutics
ACRS
$552M
| $3.57M | 0.48% |
1,888,039
+268,039
| +17% | +$444K |
2019 Q3
1 quarter
|
|
37
Viatris
VTRS
$20.7B
| $3.02M | 0.4% |
+150,000
| New | +$2.79M |
2019 Q4
0 quarters
|
|
38
Heron Therapeutics
HRTX
$57.5M
| $2.11M | 0.28% |
89,730
-8,507
| -9% | -$188K |
2014 Q1
23 quarters
|
|
39
SCYNEXIS
SCYX
$37.7M
| $1.82M | 0.24% |
+25,000
| New | +$2.06M |
2019 Q4
0 quarters
|
|
40
Palatin Technologies
PTN
$9.1M
| $819K | 0.11% |
838
| – | – |
2019 Q3
1 quarter
|
|
|
41
AbbVie
ABBV
$505B
| – | – |
-154,500
| Closed | -$11.7M | – |
|
42
ADMA Biologics
ADMA
$2.39B
| – | – |
-505,900
| Closed | -$2.25M | – |
|
43
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-880,303
| Closed | -$4.67M | – |
|
|
44
CALL
Heron Therapeutics
HRTX
$57.5M
| – | – |
-100,000
| Closed | -$1.85M | – |
|
45
SI-BONE Inc
SIBN
$963M
| – | – |
-223,291
| Closed | -$3.95M | – |
|
46
Travere Therapeutics
TVTX
$4.72B
| – | – |
-610,414
| Closed | -$7.08M | – |
|
47
Exagen
XGN
$176M
| – | – |
-311,284
| Closed | -$4.82M | – |
|
|
48
DELISTED
NEVRO CORP.
NVRO
| – | – |
-150,510
| Closed | -$12.9M | – |
|
|
MRTX
49
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-200,000
| Closed | -$15.6M | – |
|
|
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-177,016
| Closed | -$8.59M | – |
|
Similar funds
SC
Broadfin Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Broadfin Capital's Q4 2019 filing shows 12 new, 11 increased, 13 reduced and 16 closed positions. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M. The largest sale was Allergan plc, an estimated $16.2M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 59% a quarter earlier, followed by Miscellaneous.
- Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
- Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
- Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
- Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
- Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
- Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
- Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.
Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.